Last updated: August 10, 2026
TEMOVATE is the branded formulation of clobetasol propionate, an ultra-high-potency topical corticosteroid used for short-term treatment of steroid-responsive dermatoses. Its commercial trajectory is defined by long-standing generic competition, limited differentiation among dosage forms, and the absence of a meaningful remaining exclusivity barrier. The brand has low standalone revenue visibility because manufacturers generally do not disclose TEMOVATE sales separately. Financial value has shifted from the original brand to the broader clobetasol propionate market, which includes creams, ointments, gels, solutions, shampoos, foams, lotions, and sprays.
What is TEMOVATE and how is it used?
TEMOVATE contains clobetasol propionate 0.05%, a topical corticosteroid classified as super-high potency. The product has been marketed primarily in cream and ointment forms for inflammatory and pruritic corticosteroid-responsive skin conditions, including psoriasis and eczema-related disorders.
Clobetasol is generally used for short treatment courses because prolonged exposure can produce local adverse effects, hypothalamic-pituitary-adrenal axis suppression, skin atrophy, and other corticosteroid-related complications. U.S. labeling limits the amount and duration of treatment and generally discourages extended use, occlusive application, and use over large body-surface areas unless medically directed (U.S. Food and Drug Administration [FDA], 2019).
The active ingredient is not a biologic and does not require a biosimilar pathway. Competing products are approved through the abbreviated new drug application, or ANDA, pathway when they demonstrate pharmaceutical equivalence and bioequivalence to the reference product.
What is the FDA regulatory status of TEMOVATE?
TEMOVATE is an FDA-approved topical prescription corticosteroid. Its regulatory value comes from the established active ingredient, dosage strength, and recognized topical dosage forms rather than from current regulatory exclusivity.
| Regulatory attribute |
TEMOVATE position |
| Active ingredient |
Clobetasol propionate |
| Strength |
0.05% |
| Therapeutic class |
Super-high-potency topical corticosteroid |
| Primary dosage forms |
Cream and ointment; related clobetasol products include other topical forms |
| FDA pathway |
Original drug application for the reference product |
| Generic pathway |
ANDA approvals for clobetasol propionate topical products |
| Biosimilar exposure |
None |
| Prescription status |
Prescription drug |
| Current exclusivity |
No commercially significant new-drug exclusivity barrier |
| Reference-product economics |
Reduced by generic substitution and discounting |
FDA labeling identifies clobetasol propionate as a high-potency topical corticosteroid with restrictions on treatment duration and total quantity used (FDA, 2019). The FDA Orange Book identifies reference products and approved generic equivalents, but Orange Book listing status can differ by specific dosage form and product application number (FDA, 2024a).
What patents protect TEMOVATE?
No active, commercially significant patent estate is generally associated with the legacy TEMOVATE brand. The core composition and formulation protection for clobetasol propionate 0.05% products expired long ago, allowing multiple generic manufacturers to enter the U.S. market.
The principal commercial protections historically relevant to TEMOVATE were:
- Composition and active-ingredient protection for clobetasol propionate.
- Product-formulation protection for topical cream and ointment presentations.
- Regulatory exclusivity associated with the original approval.
- Trademark protection for the TEMOVATE name.
These rights do not create a current barrier to generic clobetasol products. A trademark can prevent a generic manufacturer from using the TEMOVATE name, but it does not prevent sale of an equivalent clobetasol propionate product under a different label.
What is the patent strength of the TEMOVATE estate?
The estate is weak from a market-exclusion perspective. Its key characteristics are:
| Patent factor |
Assessment |
| Core active-ingredient protection |
Expired |
| Basic cream and ointment protection |
Expired or commercially non-blocking |
| Current Orange Book blocking patents |
No material barrier generally associated with the legacy brand |
| Formulation differentiation |
Low for conventional cream and ointment products |
| Manufacturing barriers |
Low to moderate; topical semisolid manufacturing requires process controls but is not a major entry barrier |
| Litigation leverage |
Low |
| Generic substitution risk |
High |
| Lifecycle-management potential |
Limited for the legacy brand |
Later patents covering specific delivery systems, vehicles, foam technologies, or manufacturing processes may protect individual clobetasol products. Those patents generally do not restore exclusivity to the legacy TEMOVATE cream or ointment brand.
When did TEMOVATE lose exclusivity?
TEMOVATE lost meaningful market exclusivity after expiration of the original product and formulation protections, followed by approval of generic clobetasol propionate products. The precise dates depend on the original application, dosage form, and patent listing history. The commercial result is clear: generic substitution has been available for many years, and the market no longer depends on the branded product.
Unlike a recently approved specialty drug, TEMOVATE has no current five-year new chemical entity exclusivity, three-year clinical-investigation exclusivity, or orphan-drug exclusivity that would delay generic entry. Any pediatric exclusivity that may have applied historically would also have expired.
How many patents cover TEMOVATE today?
The relevant question is not the number of historical patents but whether an unexpired patent blocks an ANDA applicant. For the legacy product, no substantial blocking portfolio is generally recognized in the U.S. market.
Clobetasol products may be covered by separate patents involving:
- Aerosol foams and specialized propellants.
- Scalp or hair-bearing-area delivery systems.
- Novel emulsion or vehicle compositions.
- Combination products.
- Manufacturing processes.
- Packaging or dispensing systems.
Those rights attach to specific products and claims. They do not automatically cover all clobetasol propionate 0.05% creams or ointments.
Which companies compete with TEMOVATE?
TEMOVATE competes with a fragmented field of generic manufacturers and branded or authorized-generic products. The competitive market includes companies with topical dermatology portfolios, contract manufacturers, and large generic suppliers.
Common competitive categories include:
| Competitive category |
Examples of market participants |
| Generic clobetasol cream and ointment |
Taro, Perrigo, Glenmark, Fougera, Actavis/Teva, Mylan/Viatris and other ANDA holders |
| Branded specialty topical products |
Manufacturers with proprietary foam, lotion, spray, or scalp-delivery products |
| Retail pharmacy generics |
Private-label and pharmacy-distributed products supplied by multiple manufacturers |
| Institutional suppliers |
Generic companies serving hospitals, clinics, and dermatology practices |
| Compounded products |
Compounding pharmacies, where permitted and clinically appropriate |
The exact supplier mix varies by national market, pharmacy benefit manager, wholesaler contract, and dosage form. Cream and ointment products are the most commoditized. Specialty delivery forms can preserve higher pricing because they may improve application, spreadability, scalp delivery, or patient adherence.
What formulations are protected in the clobetasol market?
Conventional TEMOVATE cream and ointment formulations have limited differentiation. Commercial value is higher in delivery systems that address patient-use problems.
Cream and ointment
Creams generally have stronger cosmetic acceptance than ointments, while ointments can provide greater occlusion and emollience. Both forms face extensive generic competition. Product-level differentiation is usually limited to vehicle composition, excipients, package size, texture, and manufacturing consistency.
Foam
Clobetasol foam products can command higher prices than conventional creams because the dosage form is easier to spread over scalp and hair-bearing areas. Foam products may rely on patents covering the vehicle, propellant system, or manufacturing process. These patents protect the particular foam product rather than the entire clobetasol market.
Solution, shampoo, lotion, and spray
These products can target scalp disease, large or difficult-to-reach areas, or patient populations that prefer non-ointment delivery. Their commercial defenses may include formulation patents, device claims, method-of-use claims, and regulatory differentiation.
Combination and compounded products
Combination products may have separate intellectual-property positions involving additional active ingredients. Compounded clobetasol products generally do not receive the same FDA approval protections as commercial prescription products and are governed by different regulatory requirements.
Are there Paragraph IV challenges to TEMOVATE?
Paragraph IV risk is low for the legacy TEMOVATE brand because the principal generic-entry period has already passed. Paragraph IV certifications matter most when an ANDA applicant challenges an unexpired Orange Book patent. A legacy product without a meaningful blocking patent portfolio does not create the same litigation exposure as a recently launched branded drug.
Potential disputes in the broader clobetasol market are more likely to involve:
- Patents covering foam or other specialized dosage forms.
- Orange Book-listed patents for newer branded products.
- Formulation patents that distinguish a specific vehicle.
- Patent-term calculations for later-approved products.
- Trademark or trade-dress issues involving packaging and product appearance.
No major, continuing Paragraph IV dispute is central to the commercial outlook for conventional TEMOVATE cream or ointment. Orange Book patent listings should be reviewed by application number because patent status can differ between dosage forms and related clobetasol products (FDA, 2024a).
What generic entry risks exist for TEMOVATE?
Generic entry is already established rather than an upcoming risk. The principal risks are continuing price erosion, pharmacy substitution, formulary exclusion, and loss of prescriber recognition.
Generic competition affects TEMOVATE through four channels:
- Lower reimbursement for equivalent cream and ointment products.
- Automatic or pharmacist-directed substitution where permitted.
- Purchasing concentration among wholesalers and pharmacy benefit managers.
- Limited ability to raise prices without losing volume.
The remaining commercial opportunity is concentrated in product forms with greater patient convenience, differentiated delivery, or stronger physician familiarity. Conventional TEMOVATE products have little ability to defend premium pricing solely through the clobetasol active ingredient.
What is the financial trajectory of TEMOVATE?
TEMOVATE’s standalone financial trajectory is mature to declining. GSK and other historical brand owners have not consistently reported TEMOVATE revenue as a separate line item in public filings. As a result, a precise brand-revenue series cannot be derived from company annual reports.
The financial pattern is nevertheless identifiable:
| Period |
Commercial trajectory |
| Original launch and early lifecycle |
Premium branded pricing supported by product recognition and limited competition |
| Generic-entry period |
Rapid volume and price pressure following ANDA approvals |
| Mature generic market |
Low unit economics, high substitution, fragmented supplier base |
| Current market |
Brand relevance concentrated in residual prescribing, dispensing preference, and channel availability |
| Future outlook |
Stable clinical demand for clobetasol, but limited brand growth unless a differentiated delivery system is introduced |
The broader clobetasol market can remain commercially durable even while TEMOVATE brand sales decline. Dermatologic conditions requiring potent topical corticosteroids generate recurring demand, but the active ingredient is inexpensive and widely available. Revenue growth therefore depends on formulation innovation, channel expansion, geographic pricing, or branded specialty delivery rather than on the TEMOVATE name.
Does TEMOVATE face biosimilar risk?
No. TEMOVATE is a small-molecule topical drug, not a biologic. Biosimilars do not compete with it. The relevant competitive mechanisms are ANDA approvals, generic substitution, therapeutic alternatives, private-label supply, and branded reformulations.
Potential alternatives include other high-potency topical corticosteroids such as betamethasone dipropionate, fluocinonide, halobetasol propionate, and desoximetasone. Physicians select among these products based on disease location, potency, vehicle, treatment duration, patient preference, and payer coverage.
What litigation and licensing issues affect TEMOVATE?
The legacy TEMOVATE product has limited current litigation value because its core patent position is exhausted. Litigation risk is more relevant to newer clobetasol products with proprietary delivery systems or to disputes involving manufacturing and formulation claims.
No major licensing transaction is required to commercialize a standard generic clobetasol propionate cream or ointment. Generic manufacturers typically rely on their own ANDA approvals and manufacturing capabilities. Licensing becomes more relevant where a company wants access to:
- A patented foam or delivery vehicle.
- A proprietary manufacturing process.
- A branded dermatology portfolio.
- Distribution rights in a specific territory.
- An authorized-generic arrangement.
How does TEMOVATE compare with newer topical corticosteroid products?
TEMOVATE has strong historical recognition but weak current exclusivity. Newer products can have better commercial positioning if they combine clobetasol with a differentiated vehicle or delivery device.
| Attribute |
TEMOVATE cream or ointment |
Newer differentiated topical product |
| Active ingredient |
Clobetasol propionate 0.05% |
May use clobetasol or another corticosteroid |
| Generic competition |
Extensive |
Depends on formulation and patent status |
| Price power |
Low |
Moderate to high if differentiated |
| Patent strength |
Low |
Potentially stronger |
| Patient convenience |
Standard |
May improve scalp, spray, foam, or large-area application |
| Reimbursement pressure |
High |
Variable |
| Regulatory moat |
Minimal |
Product-specific |
| Revenue outlook |
Mature or declining |
Depends on adoption and exclusivity period |
What is the geographic coverage of TEMOVATE?
TEMOVATE and clobetasol propionate products have been marketed in multiple countries, but brand ownership, registration status, dosage forms, and generic availability vary by jurisdiction. U.S. economics are dominated by generic competition. European and other international markets may use different brand names, national reimbursement rules, and prescription classifications.
Geographic expansion is unlikely to produce significant value for the legacy brand unless supported by a differentiated formulation or an underpenetrated market with limited generic supply. In most mature pharmaceutical markets, clobetasol is an established generic ingredient.
Key Takeaways
- TEMOVATE is the legacy branded product for clobetasol propionate 0.05%.
- Its core patent and exclusivity position is exhausted in the U.S. commercial market.
- Generic competition is established, and conventional cream and ointment products have low pricing power.
- No biosimilar risk exists because clobetasol is a small-molecule topical drug.
- Current commercial value is concentrated in the broader clobetasol market, not the TEMOVATE brand.
- Foam, scalp, spray, lotion, and other specialized delivery systems may retain stronger formulation-based protection.
- TEMOVATE standalone revenue is not separately disclosed in a reliable public series.
- The brand’s financial trajectory is mature to declining, while demand for the active ingredient remains durable.
- Manufacturing is technically controlled but does not create a major barrier for established generic suppliers.
- The most relevant competitive threats are generic substitution, payer pressure, and branded reformulations with improved delivery.
FAQs
Is TEMOVATE still sold as a branded drug?
Availability varies by market and dosage form. In the U.S., clobetasol propionate generics are widely available, and branded TEMOVATE has much less commercial importance than the active ingredient’s generic market.
Is clobetasol stronger than hydrocortisone?
Yes. Clobetasol propionate 0.05% is classified as a super-high-potency topical corticosteroid, while hydrocortisone is generally a low-potency corticosteroid. They are not interchangeable in potency, treatment duration, or body-site restrictions.
Can a generic manufacturer launch clobetasol without licensing TEMOVATE?
Yes. A manufacturer can seek FDA approval through the ANDA pathway if its product meets applicable pharmaceutical-equivalence and bioequivalence requirements and does not infringe relevant unexpired patents.
Why do clobetasol foams cost more than TEMOVATE cream?
Foams may use proprietary vehicles, propellant systems, packaging, or delivery technologies. These features can support higher pricing and stronger patent protection than a conventional generic cream, although reimbursement and substitution still limit market access.
Does TEMOVATE have an Orange Book patent blocking generic entry?
The legacy product is not generally associated with a current, commercially meaningful patent block for conventional clobetasol cream or ointment. Product-specific Orange Book listings should be evaluated by FDA application and dosage form.
References
-
U.S. Food and Drug Administration. (2019). Temovate, clobetasol propionate cream and ointment prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, 43rd edition. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
